(Q33349331)

26 July 2017

title

The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate (English)

1 reference

26 July 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

Eric Feldman

1

1 reference

26 July 2017

Vesna Najfeld

2

1 reference

26 July 2017

Michael Schuster

3

1 reference

26 July 2017

Gail Roboz

4

1 reference

26 July 2017

Amy Chadburn

5

1 reference

26 July 2017

Richard T Silver

6

1 reference

26 July 2017

publication date

1 August 2003

1 reference

26 July 2017

published in

Experimental Hematology

1 reference

26 July 2017

volume

31

1 reference

26 July 2017

issue

8

1 reference

26 July 2017

page(s)

702-707

1 reference

Chronic myelogenous leukemia: biology and therapy

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Karyotypic and clinical progression in chronic myelogenous leukemia after 30 years

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

The incidence of trisomy 8 as a sole chromosomal aberration in myeloid malignancies varies in relation to gender, age, prior iatrogenic genotoxic exposure, and morphology

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

B-lymphoid cell involvement in chronic myelogenous leukemia: implications for the pathogenesis of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0301-472X%2803%2900176-0

7 January 2021

10.1016/S0301-472X(03)00176-0

Identifiers

DOI

1 reference

26 July 2017

1 reference